-
Sector Analysis
Ophthalmic Viscoelastic Devices (OVD) Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Ophthalmic Viscoelastic Devices (OVD) Market Report Overview The ophthalmic viscoelastic devices (OVD) market size was $1.2 billion in 2023. The market will grow at a CAGR of more than 2% during 2023-2033. Ophthalmic viscoelastic devices, also known as OVDs, are devices used during intraocular surgery, especially anterior segment surgery. These are the viscoelastic materials used to maintain space in the eye during surgery. Typically, OVDs are pre-packaged in a syringe and are applied using a small tube. Essential properties of...
-
Sector Analysis
Intraocular Lens (IOL) Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Intraocular Lens (IOL) Market Report Overview The intraocular lens (IOL) market was valued at $4.48 billion in 2023 and the market will grow at more than 2% during 2023-2033. The rising prevalence of cataracts and refractive error coupled with the increasing population around the globe has compelled governments to start initiatives toward lowering the number of patients suffering from partial or complete blindness. This, in turn, will lead to an increase in the number of eye surgeries and the use...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Triamcinolone Acetonide in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Triamcinolone Acetonide in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Triamcinolone Acetonide in Diabetic Macular Edema Drug Details: Triamcinolone acetonide...
-
Thematic Analysis
Pharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Product Insights
Glaucoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Glaucoma Clinical Trial Report Overview A total of 1,696 glaucoma clinical trials were conducted as of January 2024. The glaucoma clinical trial report provides a comprehensive understanding of the glaucoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Product Insights
NewSickle Cell Disease – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease – Drugs In Development, 2024 report and make more profitable business decisions. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewSystemic Sclerosis (Scleroderma) – Drugs In Development, 2024
Empower your strategies with our Systemic Sclerosis (Scleroderma) – Drugs In Development, 2024 report and make more profitable business decisions. Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pain, joint pain and swelling, ulcers occurring on the fingertips, bloating, and diarrhea or constipation. Treatment includes antibiotics, pain relievers, and immunosuppressants. The Systemic Sclerosis (Scleroderma) drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
NewMacular Edema – Drugs In Development, 2024
Empower your strategies with our Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the...
-
Product Insights
NewMyopia – Drugs In Development, 2024
Empower your strategies with our Myopia – Drugs In Development, 2024 report and make more profitable business decisions. Myopia, a form of nearsightedness, is a ophthalmological disorder that results in blurred vision when looking at distant objects. This occurs due to the improper refraction of light in the eye, causing the focal point to fall in front of the retina, rather than on it. Close-up objects can still be seen clearly. The underlying cause of myopia can be attributed to specific...